Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (NASDAQ: KTRA), based in San Diego, California, is a biopharmaceutical company focused on developing novel cancer therapies to address unmet medical needs. The company's core business involves the research and development of oncology drugs that target solid tumors. Kintara is currently advancing two late-stage, Phase 3-ready therapeutics: VAL-083 and REM-001. VAL-083 is a small-molecule chemotherapeutic with a unique mechanism of action, demonstrating clinical activity against a range of cancers including glioblastoma multiforme (GBM), central nervous system cancers, ovarian cancer, and other solid tumors. On the other hand, REM-001 is a photodynamic therapy (PDT) under evaluation for cutaneous metastatic breast cancer (CMBC).
In recent developments, Kintara has received an extension from Nasdaq to regain compliance with the Listing Rule 5550(b), ensuring they meet the required financial benchmarks. The company has also partnered with Ladenburg Thalmann & Co. Inc. to explore strategic alternatives aimed at maximizing shareholder value.
Recent Projects and Financial Health
Kintara launched a new 15-patient clinical trial for REM-001 for CMBC in February 2024, funded primarily by a $2.0 million grant from the National Institutes of Health (NIH). The trial aims to optimize dosage and study design ahead of a Phase 3 initiation. Financial results for the fiscal third quarter ended March 31, 2024, reveal a cash reserve of approximately $6.35 million, reflecting strengthened financials from recent stock sales and cost-cutting initiatives.
Another significant update is Kintara's planned merger with TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company. This all-stock transaction, expected to complete by Q3 2024, will result in a combined entity focused on advancing personalized cancer vaccines and bi-functional antibody drug conjugates, promising to overcome major obstacles in immunotherapy.
Conclusion
Kintara Therapeutics is dedicated to revolutionizing cancer treatment through innovative therapeutic solutions. With a robust pipeline, strategic partnerships, and a strong financial foundation, Kintara is poised to address significant gaps in cancer treatment and provide new hope to patients with limited options.
Kintara Therapeutics (KTRA) has entered into agreements to raise approximately $15 million through a registered direct offering of 12 million shares of common stock and warrants priced at $1.25 per share. The offering is expected to close around September 28, 2021. Proceeds will fund clinical studies, working capital, and potential acquisitions. H.C. Wainwright & Co. is the exclusive placement agent. The securities are offered under a shelf registration statement filed with the SEC.
Kintara Therapeutics (Nasdaq: KTRA) announced topline data from its Phase 2 clinical study of VAL-083 for newly-diagnosed glioblastoma multiforme (GBM) patients, which shows promising results. In the study, 36 efficacy evaluable patients exhibited a median progression-free survival (PFS) of 10.0 months and median overall survival (mOS) of 16.5 months. Myelosuppression was reported as the most common adverse effect, with one serious adverse event noted. VAL-083, a first-in-class treatment, continues to be evaluated as a potential breakthrough therapy for GBM patients.
Kintara Therapeutics (KTRA) announced the activation of the VAL-083 treatment arm in the registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) as of August 16, 2021. The GBM AGILE trial aims to evaluate multiple therapies at over 40 sites in the U.S. and Canada, potentially expanding to 65 sites globally. The trial is expected to expedite VAL-083's regulatory submission by up to 18 months, supported by a cost-sharing model. VAL-083 is designed to overcome MGMT resistance and has shown promise in various oncology indications.
Kintara Therapeutics (Nasdaq: KTRA) will have CEO Saiid Zarrabian present at the Investor Summit Conference on August 17, 2021, at 12:30 p.m. ET. The company focuses on developing novel cancer therapies for patients resistant to existing treatments, with two Phase 3-ready therapeutics: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. Kintara boasts an 80% complete response rate for REM-001 in clinical trials. Investors interested in one-on-one meetings can register for the event online.
Kintara Therapeutics (Nasdaq: KTRA) will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:00 p.m. ET. CEO Saiid Zarrabian will deliver a corporate presentation, followed by opportunities for one-on-one meetings. Kintara focuses on developing innovative cancer therapies, with two Phase 3-ready candidates: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. VAL-083 is a first-in-class therapy showing promise in various cancers, while REM-001 has demonstrated an 80% complete response rate in prior studies. For more details, visit www.kintara.com.
Kintara Therapeutics (Nasdaq: KTRA) announced topline results from the recurrent arm of its Phase 2 clinical trial for VAL-083 at MD Anderson Cancer Center. The trial included 89 patients with glioblastoma multiforme, showing a median overall survival (mOS) of 8.0 months for those on a 30 mg/m2/day dose, outperforming historical data for lomustine at 7.2 months. While myelosuppression was noted as a common adverse event, the results indicated VAL-083's potential in treating this challenging cancer type, with further studies planned under the GBM AGILE program.
Kintara Therapeutics (Nasdaq: KTRA) announced its addition to the Russell Microcap Index, effective June 28, 2021. This milestone is expected to enhance investor exposure to Kintara's mission of developing innovative cancer therapies. The company is advancing its lead product, VAL-083, in the GBM AGILE study for glioblastoma. Inclusion in the Russell Microcap Index provides automatic membership in growth and value style indexes, crucial as over $10.6 trillion in assets benchmark against Russell's U.S. indexes.
Kintara Therapeutics (Nasdaq: KTRA) announced the enrollment of the final patient in the adjuvant arm of its Phase 2 clinical study for VAL-083 at MD Anderson Cancer Center. This trial focuses on newly-diagnosed glioblastoma multiforme patients, replacing standard care temozolomide. The study aims to evaluate whether VAL-083 improves overall survival, using 36 patients. VAL-083 has received multiple designations from FDA and EMA, including Orphan Drug Designation for GBM. The company is also advancing its REM-001 therapy platform for metastatic breast cancer.
Kintara Therapeutics (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. His presentation is scheduled for June 9 at 2:30 pm ET, Track 1. Kintara specializes in developing novel cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in several cancers, while REM-001 has an 80% complete response rate in prior trials. Investors can register for the conference here.
Kintara Therapeutics (Nasdaq: KTRA) announced the activation of its VAL-083 treatment arm in the Global Coalition for Adaptive Research's registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM), with 15 U.S. sites active as of May 14, 2021. The GBM AGILE trial aims to enroll 150-200 patients and could expedite VAL-083's pivotal trial completion by 18 months. VAL-083 is a first-in-class treatment and may redefine therapy for various GBM subtypes. The company is focused on advancing VAL-083 alongside its REM-001 therapy for metastatic breast cancer.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
What is the primary focus of Kintara Therapeutics?
What are Kintara's main therapeutic programs?
Where is Kintara Therapeutics based?
What recent financial developments has Kintara announced?
What strategic alternatives is Kintara exploring?
What is the significance of the REM-001 clinical trial?
Has Kintara received any grants for their clinical trials?
What is VAL-083 and what cancers does it target?
How is Kintara ensuring compliance with Nasdaq listing rules?
What potential benefits are expected from the merger with TuHURA Biosciences?
